There are 2846 resources available
LBA11 - IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Presenter: Siow Ming Lee
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
Discussion: How to design better trial taking into account toxicities
Presenter: All Speakers
Session: Emerging toxicities of new anticancer therapies
Resources:
Webcast
Invited Discussant 457MO and 458MO
Presenter: Irene Brana
Session: Mini Oral session: Developmental therapeutics
Resources:
Slides
Webcast
1322MO - Selection of a set of quality indicators (QIs) on the care pathway in onco-hematology using a panel of experts
Presenter: Mario di Palma
Session: Mini Oral session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
1645O - Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
Presenter: Jaume Capdevila Castillon
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1644O and 1645O
Presenter: Marcia Brose
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Slides
Webcast
Invited Discussant LBA10 and LBA11
Presenter: Natasha Leighl
Session: Presidential Symposium III
Resources:
Slides
Webcast
459MO - Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Presenter: Manish Patel
Session: Mini Oral session: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
1318MO - Time to diagnosis among patients with cancer in the US
Presenter: Matthew Gitlin
Session: Mini Oral session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Presidential Symposium III
Resources:
Slides
Webcast